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Summary The utility of current chemotherapeutic regimens in the treatment of AIDS-related Kaposi's
sarcoma (AIDS-KS) is often compromised by both limited efficacy and substantial toxicity. Pegylated (Stealth)
liposomal doxorubicin hydrochloride (SL-DOX) has been demonstrated specifically to deliver high
concentrations of doxorubicin to Kaposi's sarcoma (KS) lesions. This phase II study was performed to
evaluate the efficacy and safety of SL-DOX in the treatment of moderate to severe AIDS-KS. Patients were
treated biweekly with 10, 20, or 40 mg m-2 SL-DOX. Tumour response was assessed according to AIDS
Clinical Trials Groups (ACTG) criteria before each cycle. Best response was determined for 238 patients and
was achieved after a mean of 2.3 cycles (range 1-20). Fifteen patients (6.3%) had a complete response to SL-
DOX, 177 (74.4%) had a partial response, 44 (18.5%) had stable disease and two (0.8%) had disease
progression. SL-DOX was well tolerated: ten patients discontinued therapy because of adverse events, in four
cases because ofneutropenia. Grade 3 or 4 neutropenia occurred after 281 of 2023 cycles (13.9%) but involved
137 of 240 patients (57.1%) for whom data were available. SL-DOX has substantial activity in AIDS-KS. Best
response is typically seen after fewer than three cycles of chemotherapy and in some cases may be prolonged.
The most important adverse event is neutropenia, which occurs after a minority ofcycles but which may occur
in over half of all patients.
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Kaposi's sarcoma (KS) is the most common neoplasm
complicating the acquired immunodeficiency syndrome
(AIDS) with a prevalence ranging from 15% to 35%
(Centers for Disease Control, 1986; Peters et al., 1991; Des
Jarlais et al., 1987).
Although the incidence of epidemic KS has declined,
greater numbers of affected patients are developing more
severe forms of the disease with gastrointestinal, respiratory
or lymphatic involvement (Des Jarlais et al., 1987). As a
consequence, KS has become an increasingly important cause
of morbidity and mortality among AIDS patients.
Cytotoxic chemotherapy, often involving doxorubicin, has
been the mainstay of treatment for severe KS. Various multi-
or single-agent regimens, however, have demonstrated either
limited efficacy or significant toxicity (Laubenstein et al.,
1984; Mintzer et al., 1985; Gelmann et al., 1987; Volberding
et al., 1985; Gill et al., 1990a and b; Kaplan et al., 1986;
Lassoued et al., 1990). No regimen has been shown to
increase patient survival (Volberding et al., 1989) and
treatment is undertaken for purposes of palliation.
Stealth liposomes are small (100 nm) unilamellar lipo-
somes which bear molecules of polyethylene glycol (PEG) on
their surface. The polymer groups provide a steric barrier
that stabilises the liposomes in plasma, thereby reducing
recognition and uptake by the reticuloendothelial system and
prolonging circulation time relative to conventional lipo-
somes (Papahadjopoulos et al., 1991). They have also been
shown to deliver significantly greater quantities of doxo-
rubicin to highly vascular KS lesions than to normal skin
(Northfelt et al., 1995). This multicentre phase II study, the
largest study to date of cytotoxic chemotherapy in the
treatment of AIDS-KS, was therefore undertaken to assess
the safety and efficacy of Stealth liposomal doxorubicin (SL-
DOX) in the treatment of moderate to severe forms of this
neoplasm.
Patients and methods
Twenty centres in seven European countries and two centres
in Australia took part in the trial (Appendix). Informed
consent was obtained in accordance with the Declaration of
Helsinki.
Study population
Patients with AIDS-related, biopsy-proven advanced KS were
eligible for the trial. HIV infection was established by ELISA
and confirmed by Western blot. Advanced KS was defined as
either visceral involvement or progressive disseminated
cutaneous disease with oedema of the face or limbs or with
oral lesions. Patients with visceral KS required measurable
skin lesions in order to be eligible for enrolment. Additional
inclusion criteria included life expectancy >8 weeks,
Karnofsky status > 50% and cardiac ejection fraction
>45% by echocardiography.
Exclusion criteria included the presence of active
opportunistic infection or non-Hodgkin's lymphoma, the
administration of systemic chemotherapy or radiotherapy
within 3 weeks before entry into the trial (or within 8 weeks
in the case of previous treatment with mitomycin, nitroso-
ureas or platinum compounds), allergy to anthracyclines,
previous cumulative anthracycline dose>200 mg m-2 and the
presence at baseline of any one of the following:
WBC<2000 mm-3; granulocyte count< 1000 mm-3; Hb
<10 g dl-'; platelet count<75 000 mm-3; prothrombin
time>twice the upper limit of normal; serum biliru-
bin>2.0 mg dl-'; serum transaminase or alkaline phospha-
tase levels >2.5 times the upper limit of normal; serum
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creatinine level>2.0 mg dl-1. Patients < 18 years of age and
female patients who were pregnant or lactating were also
excluded.
Classification ofparticipants and assessment of response
Baseline evaluation consisted of a medical history and a
physical examination. Pretreatment laboratory evaluation
included the following: complete blood cell count with
differential and platelet determination, chemistry profile,
erythrocyte sedimentation rate (ESR), serum protein electro-
phoresis and immunocytology (T cells, CD4+, CD8+, B
cells). Other evaluations included electrocardiogram, echo-
cardiogram, chest radiograph and abdominal sonography. In
patients with symptoms or signs suggestive of gastrointestinal
KS, endoscopy was performed. Bronchoscopic evaluation
was done in some patients with abnormal chest radiograph or
chest CT. All patients were asked to complete a baseline
quality-of-life assessment.
Classification of HIV-disease was carried out according to
the criteria of the Centers for Disease Control. KS stages
were defined according to the tumour-immune system-
systemic illness (TIS) classification proposed by the AIDS
Clinical Trials Group (ACTG) (Krown et al., 1989).
At baseline, five indicator lesions representative for size,
distribution and nodularity were selected, documented and
measured. Response criteria were applied as recommended by
the ACTG:
Complete response (CR) was defined as the absence of
detectable residual disease lasting for at least 4 weeks;
patients whose only remaining manifestation of KS was
pigmented macules could be classified as having had a
complete response if malignant cells were absent on biopsy of
at least one lesion. Patients with visceral disease on entry who
had complete resolution of cutaneous lesions as described
above could be considered to have had a CR only if no
residual disease was detected on endoscopic or radiographic
restaging.
Partial response (PR) was defined as a >50% decrease in
the number or size of previously existing lesions, in either
case lasting >4 weeks, with no new lesion formation or the
appearance or worsening of any lesion-associated oedema or
effusion during this time. A classification of PR required that
the product of the bidimensional diameters in no indicator
lesion increase by >25%. A classification of PR was also
made if the sum of the products of the largest perpendicular
diameters of the indicator lesions decreased by >50%, or if
>50% of nodular or plaque-like lesions became macules; if
>75% of predominantly nodular lesions flattened to
indurated plaques or if criteria for a CR were met but
lesion-associated oedema or effusion persisted. In addition,
those patients with cutaneous CR in whom invasive restaging
of visceral disease was contraindicated were considered to
have had a PR.
Stable disease (SD) was defined as any response that did
not meet criteria for CR, PR or disease progression.
Progressive disease (PD) was defined as the appearance of
new lesions, an increase of >25% in the size of previously
existing lesions, a change in character from macular to
plaque-like or nodular in >25% of previously existing lesions
or an increase in oedema or effusions.
Best response (BR) was defined as the highest level of
response achieved by the patient at any time during
treatment, using the decreasing scale CR, PR, SD and PD.
Time to treatment failure was defined as the number of days
between the beginning of treatment and the onset of
progressive disease after the patient had achieved his best
response.
Patients were evaluated weekly for toxicity; complete
blood counts were performed within 48 h before dosing
throughout the study. Biweekly efficacy evaluation included
evaluation of tumour response (after at least two cycles of
therapy), assessment of Karnofsky status and completion of
the quality-of-life questionnaire. Patients were to be with-
drawn from the study if KS did not respond or had
progressed after four doses of SL-DOX. Patients were also
to be withdrawn in the event of profound and persistent
neutropenia, anaemia or thrombocytopenia, biochemical
abnormalities, intercurrent illness interfering with participa-
tion, pregnancy, patient request, investigator discretion or
evidence of cardiotoxity. Echocardiography was repeated
after every four cycles when the cumulative dose of
doxorubicin exceeded 400 mg m-2.
Quality of life was evaluated in 214 patients using a 37-
item self-assessment questionnaire that included five domains:
functional ability (ten items), pain (two items), KS-specific
questions (four items), body image (three items) and physical
condition (18 items). The first seven questions were yes/no
questions relating to activities of daily living. The remaining
30 items had various anchored categorical responses and
addressed general physical health as well as issues related
specifically to Kaposi's sarcoma and body image.
Regimen
SL-DOX (Sequus Pharmaceuticals, Menlo Park, CA, USA)
was administered intravenously in a 30 min infusion every 2
weeks at doses of 10 mg m-2, 20 mg m-2 or 40 mg m-2.
Patients began treatment at 10 mg m-2 or 20mg m-2
depending on investigator discretion, and the dose was
titrated upwards if KS lesions failed to respond. During the
trial, dose could be titrated downward in the event of
toxicity. As a result of disease progression, ten patients
received doses of SL-DOX other than 10 mg m-2, 20 mg m-2
or 40 mg m-2 at the discretion of the investigators.
Prophylaxis against Pneumocystis carinii pneumonia (PCP)
was encouraged and concomitant nucleoside therapy
permitted. Growth factor support was also permitted to
manage neutropenia.
Statistical methods
In the time-to-event analyses (cycle number at BR, time to
BR, days to treatment failure, etc.) the mean, standard error,
median and range are computed from Kaplan-Meier curves.
In the analysis of the quality-of-life questionnaire, change
within each patient from baseline to the time of the best KS
response was analysed using a paired t-test.
Results
Patients
A total of 247 patients were enrolled. Patient demographics
are given in Table I, baseline presentation of KS in Table II
and TIS staging of KS in Table III. The median baseline
CD4 count for the 228 patients in whom it was measured was
30.5 mm-'. Of these patients, 199/228 (87.3%) had CD4
counts <200 mm-3.
One hundred and sixty-two patients (65.8%) received
prophylaxis against opportunistic infection during the course
of the trial. Of these 162 patients, 97 received sulphamethox-
Table I Patient demographics (n =247)
Age (mean+s.e.) 39.1 +0.56
Male [n (%)] 242 (98.0)
Race [n (%)]
Caucasian 230 (93.1)
Non-Caucasian 17 (6.9)
AIDS risk factor
Homosexuality 210 (85.0)
IVDAa 10 (4.0)
Other/Unknown 27 (10.9)
CD4+ mm-3 (median)b 30.5
Kamofsky score, baseline (mean ±s.e.) 75.8±1.11
aIVDA, intravenous drug abuse. bCD4 counts were measured in 228/
247 patients (92.3%).Uposomal doxorubicin phase 11
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Table II Presentation of Kaposi's sarcoma at baseline (n = 247)
Presentation Number ofpatients (%)a
Skin/subcutaneous 234 (94.7)
Oral lesions 136 (55.1)
Visceral involvement 95 (38.5)
Lung 72 (29.1)
Gastrointestinal tract 41 (16.6)
Lymph nodes 32 (12.6)
Other/unknown 17 (6.9)
aPercentages sum to more than 100 since patients could have had
lesions at more than one site.
Table III Tumour-immune system-systemic illness (TIS) staging
of Kaposi's sarcoma at entry (n =247)
TIS stage n (%)
ToloS0 14 (5.7)
ToIoS1 1 (0.4)
TOISO 54 (21.9)
T1IOSO 5 (2.0)
ToIIS 23 (9.3)
TIIoS1 5 (2.0)
TIISO 63 (25.5)
TIIS1 79 (32.0)
Unknown 3 (1.2)
azole/trimethoprim (59.9%), 82 (50.6%) pentamidine and 33
(20.4%) dapsone. One hundred and sixty-two patients were
also treated with an anti-retroviral nucleoside either before or
at the same time as SL-DOX therapy.
Of 247 patients enrolled, 167 (67.6%) received at least six
cycles of SL-DOX. One hundred and two patients (41.3%)
received at least 26 cycles of SL-DOX. The mean cumulative
dose of SL-DOX administered was 144 mg m-2 (median
120 mg m-2; range 10-520 mg m-2).
Best response for 238 patients for whom data are available
is given in Table IV. One hundred and ninety-two patients
(80.7%) achieved a complete or partial response (CI, 76% to
86%). Patients typically achieved their best response after less
than three cycles ofchemotherapy. The duration of PRs and/
or CRs is illustrated in Figure 1. Treatment failure (defined
as the development of progressive disease after the patient
had achieved his best response) occurred in 73/238 patients or
30.7% (Table V). Patients whose BR was progressive disease
were omitted from the time-to-treatment-failure analysis.
There was no statistically significant correlation between
the percentage of patients who obtained a complete or partial
response on the one hand and the baseline CD4 count
(<50 mm-3 vs>50 mm-3), baseline neutrophil count
(<2000 mm-' vs>2000 mm-3) or baseline ACTG systemic
disease status (good vs poor) (Krown et al., 1989) on the other.
Quality-of-life
Quality-of-life (QOL) questionnaires were available for 214
patients. Comparison of the mean total and mean domain
scores at baseline to mean total and domain scores at the
time patients achieved their best response showed statistically
significant improvements in the following: total score
(P<0.001), pain subscore (P=0.02), KS subscore (P=0.02)
and physical condition subscore (P=0.007). No statistically
significant changes in functional ability occurred.
Patient outcomes
Seventy patients (28.3%) died during the course of the trial.
Eleven patient deaths were considered possibly related to the
study drug by the investigators. In four of these 11 patients,
the cause of death was listed as pneumonia, in two,
pneumonia and sepsis, and in one patient each, generalised
herpes simplex viral infection, cerebral bleeding, peritonitis
Table IV Best response to SL-DOX (n=238)
Best response (BR)
Complete 15 (6.3)
Partial 177 (74.4)
Stable 44 (18.5)
Progression 2 (0.8)
Cycle no. at BR
Median
Mean (s.e.) 2.3 (0.15)
Range 1 -20
Time to BR (days)
Median 25.0
Mean (s.e.) 39.6 (2.9)
Range 1 -408
100
90
r 80
O- 70
0
= 60
.§ 50
C 40
a)
10
n 30
a)
1 20
10
0 100 200 300 400 500
Days since start PR or CR
Figure 1 Duration of response in patients with either PR or CR.
Table V Time to treatment failure (n=238)
Number (%) of patients
with treatment failure 73 (30.7)
Days to treatment failure
Median 250
Mean (s.e.) 275.5 (14.8)
Range 6* -504*
Cycle number at treatment failure 1-26*
*Censored observation (patient had not experienced treatment
failure at indicated time point).
associated with a perforated duodenal ulcer and respiratory
difficulty. The cause of death in one patient was listed as
heart failure and in another as severe oesophagogastric
candidiasis and drug-induced hepatitis.
Adverse experiences
Information on adverse experiences (AEs) is available for
245/247 patients (99.2%). A total of 1906 AEs were reported
in 239 of the 245 patients. Ten patients (4.0%) withdrew
from the study because of drug-related AEs or laboratory
abnormalities.
Possible infusion reactions occurred in 13 of 245 patients
and included dyspnoea, facial flushing, nausea and vomiting,
chest pain, facial oedema and dizziness. In three of these
patients, these reactions were judged by the investigators to
be severe. These three patients, however, recovered from the
reactions without sequelae. Two patients withdrew from the
trial because of an infusion reaction. Non-infusion-related
adverse experiences potentially related to SL-DOX are listed
in Table VI.
Cardiovascular AEsjudged probably or possibly related to
SL-DOX therapy occurred in 21 of 245 patients (8.6%).
These included four patients (1.6%) with hypotension, three
(1.2%) with pericardial effusion, three (1.2%) with throm-Liposomal doxorubicin phase 11
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bophlebitis and two each (0.8%) with heart failure and
tachycardia. No patients were withdrawn from the study
because of cardiovascular abnormalities although as noted
above, one patient died of cardiac failure considered possibly
related to study drug by the investigator. Four patients
(1.6%) developed palmar-plantar erythrodysaesthesia during
the course of therapy.
Clinical laboratory abnormalities
Clinical laboratory data were available for 247 patients
(100%). Grade 3 or 4 neutropenia (< 1000 mm-3) occurred
during 281 of 2023 cycles of chemotherapy (13.9%). Grade 3
or 4 thrombocytopenia (<50 000 mm-3) occurred during 29
cycles (1.4%). Incidence and degree of myelotoxicity are
summarised in Table VII. Four patients were withdrawn
from the study because of neutropenia.
Treatment with SL-DOX caused increases in alkaline
phosphatase (AP), aspartate aminotransferase (AST) and
total bilirubin levels. The mean+s.d. baseline alkaline AP
level for the 245/247 patients for whom data were available
was 172.0+ 136 IU L-' . At maximal individual AP levels,
the mean value rose to 327.0+ 364.5 IU L-` for the 236
patients for whom data were available. In terms of AST, the
mean+s.d. baseline value for 228 patients for whom data
were available was 25.1+27.8 IU L-', and at maximal
individual AST values, the mean value rose to
44.3+49.1 IU L-1 for the 232 patients for whom data were
available. The mean+s.d. bilirubin level at baseline was
0.5+0.4 mg dl-1 (for 237 patients) and rose at maximal
individual values to a mean+s.d. of 0.9+1.2 mg dl-1 (for
238 patients). One patient in the study died of acute hepatitis
Table VI Adverse experiences during SL-DOX therapy (n=245)
Number (%) ofpatients
Probably/possibly related to
Adverse event All AEs SL-DOX
Nausea 62 (25.3) 49 (20.0)
Vomiting 34 (13.9) 21 (8.6)
Stomatitis 29 (11.8) 23 (9.4)
Constipation 20 (8.2) 7 (2.9)
Diarrhoea 61 (24.9) 28 (11.4)
Alopecia 29 (11.8) 28 (11.4)
Table VII Incidence and degree of post-baseline neutropenia,
thrombocytopenia and anaemia by dose group
n (%)
Total patients
Minimum neutrophil count(l03 mm-3)
0.5 to <1.0
<0.5
Not available
Mean (s.e.)
Minimum platelet count (103 mm-3)
50
25 to <50
<25
Not available
Mean (s.e.)
Minimum haemoglobin (g dl-1)
247
103 (42.9)
94 (39.2)
43 (17.9)
7
1.0 (0.04)
212
13
16
140.9
(88.0)
(5.4)
(6.6)
6
(5.10)
>8 189 (78.4)
6.5 to <8 41 (17.0)
<6.5 11 (4.6)
Not avaliable 6
Mean (s.e.) 9.5 (0.12)
The minimum value obtained during the course of the trial was
selected for each measurement. Means and s.e. were computed from
patients' minima. Percentages are based on number of patients for
whom data were available.
thought to be possibly related to SL-DOX. However, no
patient was withdrawn from the study because of liver
function test abnormalities.
Opportunistic infection
A total of 286 individual events categorised as opportunistic
infections were reported in 131 of 245 patients (53.5%). Oral,
oesophageal and disseminated candidiasis represented 115 of
the 286 events. There were 44 events reported of
cytomegaloviral (CMV) infection during the study, including
CMV retinitis (22 events), gastrointestinal CMV (13 events),
pulmonary CMV (3 events) and 6 unspecified events of
CMV. In addition, there were 57 events of herpetic infection,
24 events of PCP pneumonia, 23 events of mycobacterial
infection, 12 events of toxoplasmosis and 10 events of
systemic fungal infection other than candidiasis.
Discussion
The use of conventional chemotherapy in the treatment of
epidemic KS has been limited in large measure by toxicity.
For example, doxorubicin- and etoposide-containing regi-
mens can be strongly myelosuppressive and agents that are
relatively marrow-sparing, such as vincristine, vinblastine and
bleomycin, may be burdened by other important toxicities
such as peripheral neuropathy or pulmonary fibrosis. When
myelosuppressive regimens are used, treatment with antiviral
drugs such as zidovudine and ganciclovir may have to be
suspended.
Liposomal doxorubicin has demonstrated efficacy against
a variety of murine tumours including human xenografts
(Vaage et al., 1992). Phase I clinical trials in cancer patients
showed that Stealth liposomal doxorubicin had a long plasma
half-life and increased accumulation in malignant effusions
relative to comparable doses of conventional doxorubicin
(Rahman et al., 1990; Gabizon et al., 1994). These findings
suggested that Stealth liposomal doxorubicin could have
significant advantages over the conventional formulation of
doxorubicin in the treatment of KS patients.
In this study, over 80% of patients had a best response of
either CR or PR when SL-DOX was administered biweekly.
These results compare favourably with those obtained in a
study involving 53 AIDS patients with KS given 15 mg m-2
conventional doxorubicin weekly (Fischl et al., 1993).
Only two patients completed this study from which 47 of
53 evaluable patients were withdrawn after a median
treatment duration of 2.7 months. Seventeen of these
patients (32%) were withdrawn because of toxicity and 13
(24.5%) were withdrawn because of progressive KS. Among
50 patients evaluable for efficacy, none had a CR, five (10%)
had a PR, 32 (64%) had a minor response, 12 (24%) no
change and one (2%) progression as their best response.
In a second study involving 33 patients who were treated
biweekly with a regimen incorporating conventional doxor-
ubicin (10 mg m-2 or 20 mg m-2), bleomycin 10 mg m-2 and
vincristine (1.4 mg m-2, 2 mg maximum) (Gill et al., 1990b),
26/33 patients (79%) had either a partial (18 patients) or
complete (eight patients) response. These responses were
achieved after a median of six cycles. In terms of toxicity, 11
patients (33%) developed neutrophil counts <1000 mm-3, 19
(58%) experienced nausea and/or vomiting and 20 (61%)
developed alopecia. Vincristine-related neuropathy occurred
in 20 patients (61%) and in two the severity of the
neuropathy required discontinuation of vincristine after one
or two cycles.
Other, non-anthracycline-containing chemotherapeutic
regimens have employed etoposide, vincristine, vinblastine
or bleomycin as single agents (Laubenstein et al., 1984;
Mintzer et al., 1985; Volberding et al., 1985; Lassoued et al.,
1990), or two-drug combinations ofvincristine and bleomycin
(Gill et al., 1990a), or vincristine and vinblastine (Kaplan et
al., 1986). Alpha-interferon is also used as a single agentLiposomal doxorubicin phase al
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(Gelmann et al., 1987; Lane et al., 1988). Although it is
difficult to compare results across clinical trials (in part
because of differences in the criteria used to assess response
and the small size of many of these trials), these regimens
generally appear to be less effective than combination therapy
incorporating doxorubicin.
In this trial, there was no statistically significant
correlation between the percentage of patients who achieved
PR or CR and the baseline CD4 count, neutrophil count or
ACTG systemic illness status. However, the majority of
patients in this trial were severely immunocompromised (as
indicated by the large percentage with a poor ACTG immune
system status at baseline), and it is conceivable that a
significant difference might have been observed had the study
included a larger number of less severely ill patients.
The activity and acceptable toxicity of SL-DOX in the
treatment of AIDS-KS suggest potential advantages of
liposomal drug delivery in this malignancy. In a pilot study
of liposomal daunorubicin (Presant et al., 1993), 2 of 24
evaluable patients (8.3%) had a complete response and 13
(54.2%) had a partial response. Nine patients (37.5%) had
either no response or progressive disease. Myelossuppression
was the most common adverse event in that trial, with 11 of
25 patients evaluable for toxicity (44.0%) experiencing grade
3 or 4 granulocytopenia.
Myelosuppression is also the most important toxicity of
SL-DOX. In this study, 137 of 240 patients (57.1%) for
whom data were available experienced either grade 3 or 4
neutropenia during at least one cycle of therapy. Only a
minority of cycles (13.9%) were complicated by grade 3 or 4
neutropenia, however, and only two cases of drug-related
septic infection were reported.
The elevations in hepatic enzyme levels that were observed
in this study were not clearly related to SL-DOX. It is
possible, however, that in certain cases elevation of serum
alkaline phosphatase was related to HIV-induced cholestasis
(Payne et al., 1991) aggravated in some way by the clearance
of the doxorubicin-containing liposomes by the reticuloen-
dothelial system of the liver.
The patient in whom fulminant hepatic necrosis was
ascribed to SL-DOX has been described elsewhere (Hengge et
al., 1993). This patient, who entered the study with elevated
levels of hepatic enzymes, suffered from chronic active
hepatitis B infection and had been heavily treated with
fluconazole for oesophageal candidiasis shortly before his
death. It was postulated that the hepatic necrosis seen in this
patient resulted from the combined effects of drug- and virus-
induced hepatitis.
Palmar -plantar erythrodysaesthesia syndrome was de-
scribed in four patients in this trial. This syndrome is
typically manifest as a prodrome of dysaethesias involving
the hands and feet in which an initial tingling progresses over
3 -4 days to discomfort and then to pain which is
accompanied by symmetrical swelling and erythema of the
palms, fingers and soles. If therapy is interrupted, resolution
takes place over 5-14 days with desquamation of the affected
skin. This syndrome has been reported to occur both with
SL-DOX (Gordon et al., 1995) and with continuous infusion
of doxorubicin (Lokich and Moore, 1984). In one series of 36
patients who received long-term, low-dose continuous
infusion of doxorubicin (Vogelzang and Ratain, 1985), 15
of 32 patients treated for more than 30 days developed
erythrodysaesthesia. This suggests a causal relationship
between the persistence of doxorubicin in the blood and the
occurrence of the syndrome. Such a relationship is consistent
with the significantly prolonged tl/2 and AUC for doxorubicin
that are achieved by incorporating this agent in Stealth
liposomes (Northfelt et al., 1995).
Since the mean cumulative anthracycline exposure in this
trial was relatively low (144 mg m-2), significant cardiotoxi-
city would not have been expected. Moreover, the occurrence
of HIV-associated cardiomyopathy (Grody et al., 1990)
complicates interpretation of the adverse cardiac experiences
observed here.
The 53.5% incidence of opportunistic infection on therapy
in this trial compares favorably with rates in most trials of
other chemotherapeutic regimens. In these trials, opportunis-
tic infections occurred in 11-89% of patients (Laubenstein et
al., 1984; Gill et al., 1990a,b; Fischl et al., 1993; Gill et al.,
1991). Moreover, given that 80.6% of all patients had CD4
counts on entry<200 mm-3 and that at least a third of all
trial participants received no form of prophylaxis against
Pneumocystis carinii pneumonia, the 24 cases of PCP
reported here would not have been unanticipated (Masur et
al., 1989; Fischl et al., 1988; Hirschel et al., 1991; Freedberg
et al., 1991). The same holds true for the 44 cases of
cytomegalovirus-related disease given the relationship be-
tween the probability of developing such disease and CD4
counts< 100 mm-3 (Gallant et al., 1992).
A trial comparing single-agent therapy with SL-DOX to
combination therapy with doxorubicin, vincristine and
bleomycin (ABV) is ongoing and will assess the relative
safety and efficacy of these two regimens. Phase I trials of
SL-DOX have indicated that SL-DOX has activity in breast,
ovarian, head and neck, prostatic, renal cell and non-small-
cell lung carcinomas (Uziely et al., 1995).
SL-DOX provides meaningful clinical benefits in the
single-agent therapy of AIDS-KS. At a dose of approxi-
mately 20 mg m-2 in biweekly cycles, it provides the ability
to induce partial or complete responses in a high percentage
of patients, responses that are achieved with manageable
toxicity and which, in certain cases, can be prolonged. Even
brief responses, however, can be meaningful, given the degree
of discomfort or disability experienced by these patients and
their frequently short life expectancies. This is suggested by
the statistically significant effects on quality of life at the best
KS response. It is likely that the ability specifically to deliver
relatively high doses of doxorubicin to tumour tissue with
SL-DOX will have important implications in the treatment of
other malignancies.
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